| Aug 8 |
Aptose Biosciences: Q2 Earnings Snapshot
|
| Aug 8 |
Aptose Reports Results for the Second Quarter 2024
|
| Jul 19 |
Aptose receives deficiency notice from Nasdaq
|
| Jul 19 |
Aptose Announces Receipt of Deficiency Notice from Nasdaq
|
| Jun 18 |
Aptose Announces Results from Annual and Special Meeting of Shareholders
|
| Jun 14 |
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
|
| Jun 13 |
Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
|
| Jun 3 |
Aptose Closes U$4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
| Jun 3 |
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
| May 31 |
Aptose Biosciences Down 14% In US Premarket As Plans to Raise Near $4.4 Million Via Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
